abs93.txt	objective		oncolytic	immunotherapy	involves	the	use	of	viruses	to	target	anddestroy	cancer	cells	and	induce	immune	responses	for	an	enhanced	antitumoreffect	talimogene	laherparepvec	a	genetically	modified	herpes	simplex	virustype	1	(hsv-1)	that	selectively	replicates	in	tumors	lytic	cell	death	tumor	antigen	release	local	production	granulocyte-macrophagecolony-stimulating	factor	(gm-csf)	has	been	approved	treatment	adefined	population	patients	with	metastatic	melanoma	laherparepvecis	administered	as	series	intralesional	injections	specific	proceduresare	implemented	minimize	risk	viral	exposure	because	talimogenelaherparepvec	represents	novel	therapeutic	modality	its	preparation	administration	handling	requirements	differ	from	current	therapies	pharmacists	have	important	role	developing	new	procedures	incorporate	itinto	clinical	practice	methods	this	review	experiencedispensing	trial	setting	and/or	acommercially	available	product	at	us	academic	institutions	synthesized	theirpersonal	experiences	through	group	discussions	provide	insights	on	theordering	receipt	storage	oftalimogene	results	suggestions	patient	education	andpractical	guidance	assist	hospital	decision	makers	withimplementing	their	are	provided	conclusion	these	may	further	inform	development	policies	orprocedures	into	settings	andimprove	outcomes
